Stock 2315 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Equities

2315

CNE100005D27

End-of-day quote Hong Kong S.E.
Other stock markets
 06:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
8.03 CNY -5.75% Intraday chart for Biocytogen Pharmaceuticals (Beijing) Co., Ltd. -9.67% -32.97%
May. 06 Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies CI
Apr. 26 Biocytogen Pharmaceuticals' Loss Narrows in 2023 MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • The company has insufficient levels of profitability.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. Stock Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
-32.97% 411M -
MODERNA, INC. Stock Moderna, Inc.
+51.85% 57.87B
B-
LONZA GROUP AG Stock Lonza Group AG
+41.42% 40.25B
A
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.25% 39.94B
B
CELLTRION, INC. Stock Celltrion, Inc.
-5.16% 28.54B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.79% 26.4B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.18% 19.33B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.88% 12.4B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.61% 12.23B
B+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.06% 12.2B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
-
MT Timing
-
LT Timing
-
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 2315 Stock
  4. Ratings Biocytogen Pharmaceuticals (Beijing) Co., Ltd.